Wendy L. Macias-Konstantopoulos, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Restraint, Physical | 3 | 2021 | 193 | 1.550 |
Why?
|
| Crime Victims | 5 | 2023 | 322 | 1.210 |
Why?
|
| Emergency Service, Hospital | 17 | 2023 | 7659 | 1.160 |
Why?
|
| Sex Offenses | 4 | 2022 | 354 | 1.120 |
Why?
|
| Needle-Exchange Programs | 1 | 2021 | 25 | 0.780 |
Why?
|
| Chest Pain | 2 | 2023 | 1114 | 0.710 |
Why?
|
| Harm Reduction | 1 | 2021 | 129 | 0.710 |
Why?
|
| Emergency Medicine | 3 | 2023 | 1207 | 0.690 |
Why?
|
| Drug Users | 1 | 2021 | 134 | 0.680 |
Why?
|
| Triage | 2 | 2023 | 976 | 0.660 |
Why?
|
| Abortion, Induced | 1 | 2023 | 458 | 0.610 |
Why?
|
| Women's Health Services | 1 | 2017 | 93 | 0.580 |
Why?
|
| Delivery of Health Care | 5 | 2018 | 5319 | 0.570 |
Why?
|
| Ethics, Clinical | 1 | 2017 | 101 | 0.550 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2021 | 525 | 0.550 |
Why?
|
| Women's Health | 2 | 2017 | 2034 | 0.540 |
Why?
|
| Violence | 2 | 2023 | 909 | 0.500 |
Why?
|
| Survivors | 4 | 2022 | 2291 | 0.480 |
Why?
|
| Lead Poisoning | 1 | 2016 | 304 | 0.460 |
Why?
|
| Professional Role | 1 | 2016 | 306 | 0.460 |
Why?
|
| Suicide | 1 | 2024 | 1477 | 0.450 |
Why?
|
| Antimony Potassium Tartrate | 1 | 2012 | 3 | 0.440 |
Why?
|
| Emergency Medical Services | 2 | 2023 | 1916 | 0.410 |
Why?
|
| Foreign Bodies | 1 | 2016 | 399 | 0.400 |
Why?
|
| Substance Abuse Detection | 1 | 2014 | 283 | 0.400 |
Why?
|
| Terminology as Topic | 1 | 2018 | 1548 | 0.390 |
Why?
|
| West Nile Fever | 1 | 2011 | 81 | 0.390 |
Why?
|
| Poisoning | 1 | 2012 | 249 | 0.380 |
Why?
|
| Lead | 1 | 2016 | 854 | 0.380 |
Why?
|
| Health Services Needs and Demand | 2 | 2021 | 1411 | 0.370 |
Why?
|
| Counseling | 1 | 2017 | 1523 | 0.350 |
Why?
|
| Public Health | 3 | 2021 | 2603 | 0.320 |
Why?
|
| Vulnerable Populations | 3 | 2021 | 686 | 0.300 |
Why?
|
| Health Personnel | 3 | 2017 | 3216 | 0.290 |
Why?
|
| Alcoholism | 1 | 2017 | 1906 | 0.290 |
Why?
|
| Lumbar Vertebrae | 1 | 2016 | 1848 | 0.280 |
Why?
|
| Dyspnea | 2 | 2023 | 1303 | 0.280 |
Why?
|
| Pericarditis, Constrictive | 1 | 2005 | 42 | 0.270 |
Why?
|
| Referral and Consultation | 3 | 2017 | 3528 | 0.270 |
Why?
|
| Pericardiectomy | 1 | 2005 | 45 | 0.270 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 5 | 2004 | 514 | 0.260 |
Why?
|
| Substance-Related Disorders | 3 | 2023 | 4259 | 0.260 |
Why?
|
| Corpus Striatum | 6 | 2004 | 1220 | 0.260 |
Why?
|
| Gynecology | 2 | 2017 | 513 | 0.240 |
Why?
|
| Education, Medical, Graduate | 2 | 2022 | 2291 | 0.230 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 6 | 2004 | 895 | 0.230 |
Why?
|
| Obstetrics | 2 | 2017 | 658 | 0.220 |
Why?
|
| Physician's Role | 2 | 2017 | 942 | 0.220 |
Why?
|
| Physical Exertion | 1 | 2005 | 695 | 0.220 |
Why?
|
| Curriculum | 2 | 2022 | 3604 | 0.220 |
Why?
|
| Social Stigma | 2 | 2019 | 701 | 0.210 |
Why?
|
| Humans | 45 | 2024 | 744220 | 0.210 |
Why?
|
| Human Rights Abuses | 1 | 2012 | 31 | 0.210 |
Why?
|
| Forensic Medicine | 1 | 2022 | 64 | 0.200 |
Why?
|
| Domestic Violence | 1 | 2023 | 176 | 0.200 |
Why?
|
| Mass Screening | 1 | 2017 | 5252 | 0.200 |
Why?
|
| Healthcare Disparities | 3 | 2021 | 3158 | 0.200 |
Why?
|
| Crime | 1 | 2012 | 215 | 0.190 |
Why?
|
| Potassium Chloride | 1 | 2001 | 238 | 0.190 |
Why?
|
| Pregnancy | 5 | 2024 | 29142 | 0.170 |
Why?
|
| Brazil | 1 | 2023 | 1270 | 0.170 |
Why?
|
| Paraguay | 1 | 2018 | 8 | 0.170 |
Why?
|
| Internship and Residency | 2 | 2021 | 5787 | 0.170 |
Why?
|
| Peer Group | 1 | 2023 | 635 | 0.160 |
Why?
|
| United States | 9 | 2023 | 69867 | 0.160 |
Why?
|
| Videoconferencing | 1 | 2020 | 195 | 0.160 |
Why?
|
| Health Facilities | 1 | 2023 | 573 | 0.160 |
Why?
|
| Insulinoma | 1 | 2018 | 124 | 0.150 |
Why?
|
| Health Services Accessibility | 5 | 2021 | 5138 | 0.150 |
Why?
|
| Membrane Potentials | 1 | 2001 | 1137 | 0.150 |
Why?
|
| Nurse Practitioners | 1 | 2020 | 270 | 0.150 |
Why?
|
| Beneficence | 1 | 2017 | 53 | 0.140 |
Why?
|
| Confusion | 2 | 2018 | 275 | 0.140 |
Why?
|
| Feedback | 1 | 2020 | 795 | 0.140 |
Why?
|
| Chelation Therapy | 1 | 2016 | 67 | 0.140 |
Why?
|
| Air Ambulances | 1 | 2007 | 90 | 0.140 |
Why?
|
| Child | 6 | 2024 | 77679 | 0.130 |
Why?
|
| Documentation | 1 | 2022 | 869 | 0.130 |
Why?
|
| Bioethics | 1 | 2017 | 116 | 0.130 |
Why?
|
| Alcohol Withdrawal Seizures | 1 | 2015 | 10 | 0.130 |
Why?
|
| Female | 19 | 2024 | 380197 | 0.130 |
Why?
|
| Acetone | 1 | 2015 | 43 | 0.130 |
Why?
|
| Alcohol Withdrawal Delirium | 1 | 2015 | 27 | 0.130 |
Why?
|
| Gestational Age | 1 | 2023 | 3493 | 0.130 |
Why?
|
| Communication Barriers | 1 | 2018 | 398 | 0.130 |
Why?
|
| Needs Assessment | 2 | 2018 | 1147 | 0.120 |
Why?
|
| Resource Allocation | 1 | 2017 | 341 | 0.120 |
Why?
|
| Personal Autonomy | 1 | 2017 | 298 | 0.120 |
Why?
|
| Amphetamine-Related Disorders | 1 | 2014 | 67 | 0.120 |
Why?
|
| Risk Factors | 6 | 2018 | 72280 | 0.120 |
Why?
|
| Adult | 13 | 2023 | 214035 | 0.120 |
Why?
|
| Disclosure | 1 | 2019 | 736 | 0.120 |
Why?
|
| Cause of Death | 1 | 2024 | 3584 | 0.110 |
Why?
|
| International Classification of Diseases | 1 | 2018 | 867 | 0.110 |
Why?
|
| Mothers | 1 | 2024 | 2165 | 0.110 |
Why?
|
| Calcium Channels, L-Type | 3 | 2004 | 240 | 0.110 |
Why?
|
| Psychomotor Agitation | 1 | 2015 | 293 | 0.110 |
Why?
|
| Receptors, Dopamine D1 | 2 | 2004 | 291 | 0.110 |
Why?
|
| Tachycardia | 1 | 2015 | 620 | 0.110 |
Why?
|
| Social Justice | 1 | 2017 | 456 | 0.100 |
Why?
|
| Infant | 2 | 2024 | 35129 | 0.100 |
Why?
|
| Europe | 1 | 2018 | 3339 | 0.100 |
Why?
|
| Health Services | 1 | 2017 | 758 | 0.100 |
Why?
|
| Family Relations | 1 | 2013 | 321 | 0.100 |
Why?
|
| Developing Countries | 1 | 2024 | 2814 | 0.100 |
Why?
|
| Patient Transfer | 1 | 2018 | 761 | 0.100 |
Why?
|
| Child Abuse, Sexual | 1 | 2013 | 383 | 0.100 |
Why?
|
| Hypoglycemia | 1 | 2018 | 861 | 0.100 |
Why?
|
| Professional-Patient Relations | 1 | 2016 | 737 | 0.100 |
Why?
|
| Cocaine-Related Disorders | 1 | 2014 | 460 | 0.090 |
Why?
|
| Liver Failure, Acute | 1 | 2012 | 165 | 0.090 |
Why?
|
| Clinical Protocols | 1 | 2016 | 1462 | 0.090 |
Why?
|
| Social Medicine | 1 | 2010 | 62 | 0.090 |
Why?
|
| Marijuana Abuse | 1 | 2014 | 403 | 0.090 |
Why?
|
| Wounds, Gunshot | 1 | 2016 | 563 | 0.090 |
Why?
|
| Neurons | 6 | 2004 | 9335 | 0.090 |
Why?
|
| Kenya | 2 | 2022 | 685 | 0.090 |
Why?
|
| Interviews as Topic | 2 | 2013 | 2539 | 0.090 |
Why?
|
| Vomiting | 1 | 2012 | 635 | 0.080 |
Why?
|
| Social Environment | 1 | 2013 | 1023 | 0.080 |
Why?
|
| Social Support | 1 | 2018 | 2117 | 0.080 |
Why?
|
| Patient Discharge | 1 | 2021 | 3313 | 0.080 |
Why?
|
| Attitude of Health Personnel | 2 | 2020 | 3842 | 0.080 |
Why?
|
| Research | 1 | 2016 | 1999 | 0.080 |
Why?
|
| Calcium Channel Agonists | 3 | 2003 | 29 | 0.080 |
Why?
|
| Nifedipine | 2 | 2004 | 226 | 0.070 |
Why?
|
| Diagnosis, Differential | 3 | 2018 | 12961 | 0.070 |
Why?
|
| Cyclic AMP | 2 | 2003 | 1471 | 0.070 |
Why?
|
| Excitatory Amino Acid Antagonists | 4 | 2004 | 449 | 0.070 |
Why?
|
| Mental Health Services | 1 | 2018 | 1643 | 0.070 |
Why?
|
| Patient-Centered Care | 1 | 2016 | 1438 | 0.070 |
Why?
|
| Human Rights | 2 | 2022 | 307 | 0.060 |
Why?
|
| Patient Care Team | 1 | 2016 | 2529 | 0.060 |
Why?
|
| Alcohol Drinking | 1 | 2017 | 3966 | 0.060 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 3227 | 0.060 |
Why?
|
| Calcium | 5 | 2004 | 5757 | 0.060 |
Why?
|
| Education, Medical | 1 | 2016 | 1721 | 0.060 |
Why?
|
| Calcium Channel Blockers | 2 | 2004 | 690 | 0.060 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 3023 | 0.060 |
Why?
|
| Comorbidity | 1 | 2018 | 10387 | 0.060 |
Why?
|
| Male | 11 | 2021 | 350027 | 0.060 |
Why?
|
| Health Policy | 1 | 2016 | 2661 | 0.060 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 2003 | 57 | 0.060 |
Why?
|
| Wounds and Injuries | 1 | 2016 | 2400 | 0.060 |
Why?
|
| Infant, Newborn | 1 | 2024 | 25618 | 0.060 |
Why?
|
| Telemedicine | 1 | 2021 | 2872 | 0.060 |
Why?
|
| Opioid-Related Disorders | 1 | 2018 | 2065 | 0.060 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 2 | 2003 | 494 | 0.060 |
Why?
|
| Enkephalins | 1 | 2003 | 154 | 0.060 |
Why?
|
| Renal Dialysis | 1 | 2012 | 1787 | 0.050 |
Why?
|
| Sexual Behavior | 2 | 2022 | 2056 | 0.050 |
Why?
|
| Physicians | 1 | 2020 | 4564 | 0.050 |
Why?
|
| Crisis Intervention | 1 | 2023 | 105 | 0.050 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 1 | 1 | 2001 | 18 | 0.050 |
Why?
|
| Primary Health Care | 1 | 2018 | 4556 | 0.050 |
Why?
|
| Phosphorylation | 6 | 2004 | 8437 | 0.050 |
Why?
|
| Serum Response Factor | 1 | 2001 | 81 | 0.050 |
Why?
|
| Exercise Tolerance | 1 | 2005 | 770 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 5257 | 0.050 |
Why?
|
| Pyrroles | 3 | 2003 | 1143 | 0.050 |
Why?
|
| Patient Isolation | 1 | 2021 | 100 | 0.050 |
Why?
|
| Incidence | 1 | 2018 | 20945 | 0.050 |
Why?
|
| Health Status | 1 | 2013 | 4034 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2020 | 23337 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 7784 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2023 | 780 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2023 | 77426 | 0.040 |
Why?
|
| Receptors, GABA | 1 | 2001 | 288 | 0.040 |
Why?
|
| Protein Precursors | 1 | 2003 | 1154 | 0.040 |
Why?
|
| Photography | 1 | 2022 | 520 | 0.040 |
Why?
|
| Carboxypeptidases | 1 | 1999 | 176 | 0.040 |
Why?
|
| Rats | 7 | 2004 | 24273 | 0.040 |
Why?
|
| Glutamic Acid | 2 | 2003 | 1169 | 0.040 |
Why?
|
| Adolescent | 2 | 2017 | 85759 | 0.040 |
Why?
|
| Job Satisfaction | 1 | 2021 | 535 | 0.040 |
Why?
|
| Morbidity | 1 | 2022 | 1769 | 0.040 |
Why?
|
| Dizocilpine Maleate | 3 | 2004 | 176 | 0.040 |
Why?
|
| Prevalence | 1 | 2013 | 15226 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 1999 | 575 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 6 | 2004 | 8302 | 0.030 |
Why?
|
| Housing | 1 | 2021 | 664 | 0.030 |
Why?
|
| Cells, Cultured | 5 | 2004 | 19227 | 0.030 |
Why?
|
| Calcium Channels | 1 | 1999 | 622 | 0.030 |
Why?
|
| Health Services Research | 1 | 2023 | 1836 | 0.030 |
Why?
|
| Hyperinsulinism | 1 | 2018 | 415 | 0.030 |
Why?
|
| Young Adult | 3 | 2020 | 56436 | 0.030 |
Why?
|
| Radiography, Abdominal | 1 | 2018 | 537 | 0.030 |
Why?
|
| Antigens, Surface | 1 | 1999 | 1663 | 0.030 |
Why?
|
| Stroke | 1 | 2007 | 9981 | 0.030 |
Why?
|
| Consensus | 1 | 2023 | 2958 | 0.030 |
Why?
|
| Sulfonamides | 1 | 2003 | 1940 | 0.030 |
Why?
|
| Gene Expression Regulation | 3 | 2001 | 12075 | 0.030 |
Why?
|
| Fetus | 1 | 2001 | 1880 | 0.030 |
Why?
|
| Resilience, Psychological | 1 | 2020 | 675 | 0.030 |
Why?
|
| Motivation | 1 | 2023 | 1971 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2003 | 3617 | 0.030 |
Why?
|
| Leadership | 1 | 2021 | 1357 | 0.030 |
Why?
|
| Burnout, Professional | 1 | 2020 | 694 | 0.030 |
Why?
|
| Hair | 1 | 2014 | 483 | 0.020 |
Why?
|
| Philippines | 1 | 2010 | 86 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 2759 | 0.020 |
Why?
|
| Drug Interactions | 2 | 2004 | 1458 | 0.020 |
Why?
|
| Neuronal Plasticity | 1 | 1998 | 1422 | 0.020 |
Why?
|
| Middle Aged | 4 | 2020 | 213367 | 0.020 |
Why?
|
| Hippocampus | 1 | 2001 | 3676 | 0.020 |
Why?
|
| Health Promotion | 1 | 2020 | 2205 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2007 | 2486 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2003 | 1724 | 0.020 |
Why?
|
| Boston | 1 | 2021 | 9311 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2020 | 9849 | 0.020 |
Why?
|
| Massachusetts | 1 | 2020 | 8663 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2023 | 13990 | 0.020 |
Why?
|
| Antipsychotic Agents | 1 | 2000 | 3058 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2001 | 5853 | 0.020 |
Why?
|
| 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine | 1 | 2004 | 54 | 0.020 |
Why?
|
| Dopamine Antagonists | 1 | 2004 | 296 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 19907 | 0.010 |
Why?
|
| Heart Rate | 1 | 2015 | 4092 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2001 | 9647 | 0.010 |
Why?
|
| Pandemics | 1 | 2023 | 8387 | 0.010 |
Why?
|
| Brain Ischemia | 1 | 2007 | 3265 | 0.010 |
Why?
|
| Animals | 7 | 2004 | 168788 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2004 | 433 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2003 | 821 | 0.010 |
Why?
|
| Isoquinolines | 1 | 2003 | 368 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2015 | 6442 | 0.010 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2003 | 491 | 0.010 |
Why?
|
| Carcinogens | 1 | 2003 | 466 | 0.010 |
Why?
|
| Genes, fos | 1 | 2000 | 183 | 0.010 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2000 | 147 | 0.010 |
Why?
|
| Cycloserine | 1 | 2000 | 113 | 0.010 |
Why?
|
| Receptors, Kainic Acid | 1 | 1999 | 88 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2015 | 8551 | 0.010 |
Why?
|
| Neostriatum | 1 | 2000 | 250 | 0.010 |
Why?
|
| Receptors, Glutamate | 1 | 1999 | 232 | 0.010 |
Why?
|
| Haloperidol | 1 | 2000 | 397 | 0.010 |
Why?
|
| Glutamate Carboxypeptidase II | 1 | 1999 | 77 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2000 | 1581 | 0.010 |
Why?
|
| Aged | 2 | 2023 | 163253 | 0.010 |
Why?
|
| Receptors, AMPA | 1 | 1999 | 331 | 0.010 |
Why?
|
| Culture Techniques | 1 | 1998 | 554 | 0.010 |
Why?
|
| Embryo, Mammalian | 1 | 2003 | 1701 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2003 | 1782 | 0.010 |
Why?
|
| Clozapine | 1 | 2000 | 498 | 0.010 |
Why?
|
| Magnesium | 1 | 1999 | 813 | 0.010 |
Why?
|
| Benzazepines | 1 | 1998 | 326 | 0.010 |
Why?
|
| Immunoblotting | 1 | 1999 | 1682 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 20123 | 0.010 |
Why?
|
| Dopamine Agonists | 1 | 1998 | 355 | 0.010 |
Why?
|
| Transfection | 1 | 2003 | 5892 | 0.010 |
Why?
|
| Time Factors | 1 | 2007 | 40063 | 0.010 |
Why?
|
| Zinc | 1 | 1999 | 683 | 0.010 |
Why?
|
| Sodium | 1 | 1999 | 1623 | 0.010 |
Why?
|
| Antihypertensive Agents | 1 | 2003 | 2047 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1999 | 3133 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2003 | 3800 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2007 | 57768 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 35423 | 0.010 |
Why?
|
| Dopamine | 1 | 1998 | 1591 | 0.010 |
Why?
|
| Binding Sites | 1 | 1999 | 6116 | 0.010 |
Why?
|
| Signal Transduction | 2 | 2003 | 23404 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2014 | 63119 | 0.000 |
Why?
|